Vertical Expandable Prosthetic Titanium Rib (VEPTR) for Thoracic Insufficiency Syndrome (VEPTR)

Ertical Expandable Prosthetic Titanium Rib (VEPTR) for Thoracic Insufficiency Syndrome

The hypothesis of the study is that individuals with poor pulmonary function secondary to TIS will benefit from expansion thoracoplasty. The investigators specific aims are to:

1. Record pulmonary function and thoracic volume of TIS patients at enrollment and with serial observation

2. Offer expansion thoracoplasty therapy to TIS patients with

   1. poor pulmonary function at enrollment
   2. progressive decline in pulmonary function
   3. progressive chest wall and/or spinal deformity
   4. lack of appropriate increase in thoracic volume during growth
3. Document efficacy of expansion thoracoplasty for TIS patients

Study Overview

• Status: Completed
• Conditions: Thoracic Insufficiency Syndrome (TIS)
• Intervention / Treatment: Device: Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)

Detailed Description

Study procedures

1. Patient Identification & Enrollment Patients meeting the inclusion criteria will be invited to enroll in the study as described above.

2. Serial clinical observation

   Patients will be followed over time for progression of thoracic insufficiency indicators:

   • Worsening respiratory status oFrequent respiratory infections oElevated resting respiratory rate oEase of fatigability oHypoxia and hypercapnia oMarionette sign (trunk and shoulder elevation and depression with respiration)
   • Primary diaphragmatic breathing (loss of chest wall mobility)
   • Progressive scoliosis
   • Failure of thoracic dimensions to increase with growth

   Patients with progressive thoracic insufficiency will be offered surgical intervention with expansion thoracoplasty utilizing the VEPTR device.

   Studies which are standard of care for TIS will be utilized to assess patients. Routine standard of care studies will be obtained:

   1. MRI of the spine will be obtained at presentation.
   2. Chest CT scan (every 2 years, or less frequently if clinically indicated)
   3. AP/Lat spine xrays (to include the chest wall)
   1. Will be obtained every 6 months - 12 months
   2. If a patient has a VEPTR implantation, the typical schedule of radiographs would include immediate postoperative xrays (the day of surgery and/or early postoperative period) and at 6 weeks, 12 weeks, and 6 months postoperative.
   3. VEPTR lengthening will typically take place every 6 months after the initial VEPTR implantation.

   i.Xrays will be obtained every 6 months in association with the VEPTR lengthening.

   ii.Once VEPTR lengthening is no longer clinically indicated, the patients will be followed with xrays every 6-24 months until skeletal maturity.

   d.Pulmonary function tests (spirometry) will be obtained every 6-12 months in children who are old enough to participate (typically > age 4 years).

   e.Arterial and/or capillary blood gases

   a.Blood gases will be obtained every 6-12 months if clinically indicated and perioperatively for VEPTR implantation / lengthening.

   f.Routine vital signs including resting pulse oximetry (SaO2)

   a.Will be assessed at clinic visits and perioperatively g.All of the above mentioned studies will be obtained more or less frequently as clinically indicated.

3. Expansion thoracoplasty with VEPTR implantation and subsequent lengthening with the VEPTR will be performed following informed consent. The surgical technique will be as described by Campbell.3 The VEPTR device will be lengthened at 6 to 12 month intervals until thoracic and spinal deformities have stabilized radiographically.

• Study Type: Observational
• Enrollment (Actual): 7

Contacts and Locations

Study Locations

• United States
  • Tennessee
    • Nashville, Tennessee, United States, 37232
      • Monroe Carell Jr. Children's Hospital at Vanderbilt

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 13 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Pediatric patients, age range from 6 months to 17 years with thoracic insufficiency syndrome (TIS). Categories of TIS include:

1. Flail chest syndrome
2. Constrictive chest wall syndrome (rib fusions and scoliosis)
3. Hypoplastic thorax syndrome (Jeune's syndrome, achondroplasia, Jarcho-levin syndrome, Ellis van Creveld syndrome)
4. Progressive scoliosis/kyphosis of congenital, neurogenic, or idiopathic origin without rib anomaly
5. Early onset scoliosis without rib anomaly at high risk for progression

Description

Inclusion Criteria:

• Pediatric patients, age range from 6 months - 17 years with thoracic insufficiency syndrome (TIS) will be considered for inclusion. Categories of TIS include:

  1. Flail chest syndrome
  2. Constrictive chest wall syndrome (rib fusions and scoliosis)
  3. Hypoplastic thorax syndrome (Jeune's syndrome, achondroplasia, Jarcho-levin syndrome, Ellis van Creveld syndrome)
  4. Progressive scoliosis/kyphosis of congenital, neurogenic, or idiopathic origin without rib anomaly
  5. Early onset scoliosis without rib anomaly at high risk for progression

Exclusion Criteria:

• Failure to meet inclusion criteria.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Expansion Thoracoplasty; The rib prosthesis is lengthened periodically to correct the concavity of the deformity, expanding the volume of the hypoplastic thorax and improving associated spinal deformity. This device has been FDA approved by a Humanitarian Device Exemption and is described as a Vertical Expandable Prosthetic Titanium Rib (VEPTR). An updated version of the VEPTR, the VEPTR II, may be used instead depending on the physician's preference and the patient's anatomy. The VEPTR II device has greater size range and modularity of implants than the original VEPTR.

Device: Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulmonary function and thoracic volume of TIS patients	1)Record pulmonary function and thoracic volume of TIS patients at enrollment and with serial observation postoperatively (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.)	Enrollment (Baseline), Serial Observation Postop (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.)
ffer expansion thoracoplasty therapy to TIS patients meeting certain criteria (provided in description below)	Offer expansion thoracoplasty therapy to TIS patients with; poor pulmonary function at enrollment; progressive decline in pulmonary function; progressive chest wall and/or spinal deformity; lack of appropriate increase in thoracic volume during growth	Enrollment (Baseline), Serial Observation Postop (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.)
Document efficacy of expansion thoracoplasty for TIS patients		Enrollment (Baseline), Serial Observation Postop (Change from baseline at: 6 week, 12 week, 6 month, and every 6 months after that.)

Collaborators and Investigators

• Sponsor: Vanderbilt University Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): November 11, 2010
• Primary Completion (Actual): March 25, 2018
• Study Completion (Actual): February 28, 2020

Study Registration Dates

• First Submitted: September 3, 2014
• First Submitted That Met QC Criteria: September 15, 2014
• First Posted (Estimate): September 16, 2014

Study Record Updates

• Last Update Posted (Actual): May 12, 2020
• Last Update Submitted That Met QC Criteria: May 11, 2020
• Last Verified: May 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease; Syndrome
• Other Study ID Numbers: 091371

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No